Becton, Dickinson and Company
) has globally launched its latest glass prefillable syringe
system, the BD Neopak. The advanced device is used for
biopharmaceutical injectable drug delivery.
The BD Neopak Glass Prefillable Syringe provides high quality
container and device integration support, which in turn allows
its pharmaceutical customers to safely deliver drugs to patients.
The fully indexed lines on the syringe with no possibility of
glass-to-glass contact limit visual defects and strengthens the
quality of the glass. The new process also reduces silicone
The unique design of the prefillable syringe system helps to
optimize filling of biologic drugs, among the top selling drugs
in the world. The BD XSi cross-linked silicone technology and the
ultralow tungsten technology in the BD Neopak, further aids BD's
pharmaceutical clients to market sensitive drugs.
BDX will provide additional services such as customized drug
compatibility assessments, functional requirements (drug and
system related) as well as registration and post-launch help to
aid drug development with the BD Neopak.
The worldwide commercial launch of this new offering should boost
the company's Pharmaceutical System division's revenues under the
BD Medical segment. In the last reported quarter, sales of this
franchise were up 3.0% (up 2.4% in constant currency) to $291.4
The stock currently carries a Zacks Rank #2 (Buy). We remain
encouraged by the company's solid fiscal second-quarter results,
which exceeded expectations. Moreover, the upward revision in
guidance for the ongoing fiscal reflects positive drivers.
Becton Dickinson's preeminent global healthcare products
franchise is partly insulated from volatile macroeconomic
conditions and structural deficiencies elsewhere in the
healthcare delivery field.
Other medical stocks that warrant a look include
The Cooper Companies
West Pharmaceutical Services
). All the stocks carry a Zacks Rank #2 (Buy).
BECTON DICKINSO (BDX): Free Stock Analysis
CONMED CORP (CNMD): Free Stock Analysis
COOPER COS (COO): Free Stock Analysis Report
WEST PHARM SVC (WST): Free Stock Analysis
To read this article on Zacks.com click here.